Restrictive Lung Function Is Related to Sympathetic Hyperactivity in Patients With Heart Failure

Joho, Shuji; Ushijima, Ryuichi; Akabane, T; Hirai, Tadakazu; Inoue, Hiroshi

doi:10.1016/j.cardfail.2016.06.001

Cited by 10 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sympathetic innervation is known to increase pulmonary capillary leakage and favor ARDS [59–62]. Restrictive lung function has been associated with increased sympathetic nerve activity in heart failure, possibly due to interstitial pulmonary edema or changes in alveolar capillary units [63].…”

Section: Sympathetic Overactivity May Exert Significant Detrimental Ementioning

confidence: 99%

See 1 more Smart Citation

Sympathetic activation: a potential link between comorbidities and COVID‐19

et al. 2020

View full text Add to dashboard Cite

In coronavirus disease 2019 (COVID‐19), higher morbidity and mortality are associated with age, male gender, and comorbidities, such as chronic lung diseases, cardiovascular pathologies, hypertension, kidney diseases, diabetes mellitus, and obesity. All of the above conditions are characterized by increased sympathetic discharge, which may exert significant detrimental effects on COVID‐19 patients, through actions on the lungs, heart, blood vessels, kidneys, metabolism, and/or immune system. Furthermore, COVID‐19 may also increase sympathetic discharge, through changes in blood gases (chronic intermittent hypoxia, hyperpnea), angiotensin‐converting enzyme (ACE)1/ACE2 imbalance, immune/inflammatory factors, or emotional distress. Nevertheless, the potential role of the sympathetic nervous system has not yet been considered in the pathophysiology of COVID‐19. In our opinion, sympathetic overactivation could represent a so‐far undervalued mechanism for a vicious circle between COVID‐19 and comorbidities.

show abstract

Section: Sympathetic Overactivity May Exert Significant Detrimental Ementioning

confidence: 99%

“…Restrictive lung function has been associated with increased sympathetic nerve activity in heart failure, possibly due to interstitial pulmonary edema or changes in alveolar capillary units [63].…”

Section: Sympathetic Overactivity May Exert Significant Detrimental Effects On Covid-19 Patientsmentioning

confidence: 99%

Sympathetic activation: a potential link between comorbidities and COVID‐19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…All parameters were obtained in resting patients who were awake and in a supine position, as previously described [20][21][22]. Briefly, blood pressure was serially recorded using noninvasive tonometry (Jentow 7700, Colin, Komaki, Japan).…”

Section: Measurement Of Blood Pressure Respiration and Muscle Sympathetic Nerve Activitymentioning

confidence: 99%

“…Briefly, blood pressure was serially recorded using noninvasive tonometry (Jentow 7700, Colin, Komaki, Japan). Multiunit recordings of efferent postganglionic sympathetic nerve activity to skeletal muscle regions were captured via a microelectrode inserted directly into the peroneal nerve posterior to the fibular head [20][21][22]. The nerve signal was amplified Â100,000, passed through a band-pass filter (500-5000 Hz), and integrated with a custom nerve-traffic analysis system (NeuropackS MEB-5504, Nihon Kohden, Tokyo, Japan).…”

Section: Measurement Of Blood Pressure Respiration and Muscle Sympathetic Nerve Activitymentioning

confidence: 99%

Relation between prognostic impact of hyperuricemia and sympathetic overactivation in patients with heart failure

Joho

Ushijima

Nakagaito

et al. 2019

Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Background: Uric acid (UA), which could provide additional prognostic information in patients with heart failure (HF), can activate sympathetic nerve activity and vice versa, thus creating a vicious cycle in the cardiovascular system. However, it remains unclear whether hyperuricemia (UA > 7.0 mg/dl) can provide prognostic information independent of sympathetic nerve activity. Methods: UA and potential prognostic variables including sympathetic nerve activity using microneurography (MSNA) were evaluated in 139 patients with HF (ejection fraction < 45%). Primary composite cardiovascular endpoints included cardiovascular death and hospitalization due to HF. Predictors for outcomes were analyzed using univariate, multivariable, and Kaplan-Meier analyses. To determine whether the negative impact of hyperuricemia on outcomes is homogenous, prognostic impacts of hyperuricemia were compared in subgroups of HF. Ejection fraction was followed for 9 months after MSNA measurement in 102 patients. Results: During a follow-up period of 1636 days, 54 patients fulfilled the primary composite endpoint of cardiovascular death or HF hospitalization. Patients with hyperuricemia had a higher cardiovascular event rate than those with normouricemia (p = 0.006). On multivariable Cox proportional hazard analysis, hyperuricemia, higher MSNA, and b-blocker dose were independent predictors of cardiovascular events. In subgroup analyses, impact of hyperuricemia on outcome was similar in all subgroups except sympathetic nerve activity (interaction, p = 0.033). Hyperuricemia had negative impact on cardiovascular event rates (hazard ratio = 3.44) in group with higher MSNA (p = 0.0002), but not in those with lower MSNA. Additionally, the change in LVEF was also significantly lower in patients who had a higher MSNA burst incidence and hyperuricemia. Conclusion: Hyperuricemia might have detrimental effect on prognosis and cardiac function in HF patients with sympathetic overactivation.

show abstract

“…Logo, se faz necessário investigar a função pulmonar, uma vez que há poucas pesquisas em pacientes com AOS (Tassinari et al, 2016). Vários estudos sugerem que a redução no volume pulmonar pode agravar tanto a AOS (Bikov, Losonczy & Kunos, 2017;Carvalho et al, 2018;Santos et al, 2018;Tassinari et al, 2016) quanto a ICC (Forgiarini et al, 2007;Johnson et al 2001;Joho et al, 2017), o que prediz piores desfechos aos pacientes.…”

Section: Introductionunclassified

Força muscular inspiratória e função pulmonar em pacientes com insuficiência cardíaca crônica e apneia obstrutiva do sono

Parizotto

Bortagarai²,

Moreira

et al. 2021

RSD

View full text Add to dashboard Cite

Objetivo: Avaliar a força dos músculos inspiratórios e a função pulmonar em pacientes com insuficiência cardíaca crônica (ICC) e apneia obstrutiva do sono (AOS). Métodos: Estudo transversal com 18 participantes com ICC (12 homens) apresentando fração de ejeção do ventrículo esquerdo (FEVE) reduzida (< 51% para homens e < 53% para mulheres), acometidos por AOS (leve a grave) diagnosticada através do exame de polissonografia portátil. A força muscular inspiratória foi mensurada pela determinação da pressão inspiratória máxima (Pimáx) através de manovacuometria e comparado aos valores preditos para o sexo e idade. A capacidade vital forçada (CVF), volume expiratório forçado no primeiro segundo (VEF1) e índice de tiffenau (CVF/VEF1) foram mensurados através de um espirômetro computadorizado e foram comparados aos valores preditos. Resultados: A força muscular inspiratória dos pacientes com ICC e AOS (109 ± 29 cmH2O) encontrou-se preservada em comparação aos valores preditos para o sexo e idade (100 ± 13cmH2O; p= 0,22). Ambos, CVF e VEF1 encontraram-se diminuídos em relação aos valores preditos (p= 0,001). Conclusões: Pacientes com ICC e AOS apresentaram força muscular inspiratória preservada e função pulmonar diminuída em relação aos valores de referência.

show abstract

Restrictive Lung Function Is Related to Sympathetic Hyperactivity in Patients With Heart Failure

Cited by 10 publications

References 30 publications

Sympathetic activation: a potential link between comorbidities and COVID‐19

Sympathetic activation: a potential link between comorbidities and COVID‐19

Relation between prognostic impact of hyperuricemia and sympathetic overactivation in patients with heart failure

Força muscular inspiratória e função pulmonar em pacientes com insuficiência cardíaca crônica e apneia obstrutiva do sono

Contact Info

Product

Resources

About